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1. Introduction 
Lipoproteins are complexes consisting of a lipid core of mainly triglycerides and cholesterol 
esters surrounded by a surface monolayer of phospholipids, free cholesterol and specific 
protein components named apolipoproteins [1]. Most apolipoproteins undergo complex 
exchange reactions and serve many metabolic functions including transport, enzyme 
cofactors and receptor ligands. Except for the covalently linked apolipoprotein(a)-
apolipoproteinB-100 (apo(a)-apoB) complex in Lipoprotein(a) [Lp(a)], apolipoproteins are 
non-covalently associated with each other and the lipid core. 
Lipoprotein disorders are often associated with cardiovascular disease (CVD), 
atherosclerosis and other organ dysfunctions [2, 3]. To prevent and treat these diseases and 
to fully understand their cause, it is necessary to characterise the underlying metabolic 
disorders [1]. The conventional initial approach to do this is by measuring concentrations of 
plasma lipids or apolipoproteins. However, abnormal concentrations of lipids and 
apolipoproteins can result from changes in the production, conversion or catabolism of 
lipoprotein particles. Therefore, although static measurements and functional assays are 
important techniques to gain first in vivo functional insights, it is necessary to study their 
metabolic pathway to understand the complexity of lipoprotein function and 
pathophysiology [4, 5]. 
Animal models cannot sufficiently replace human studies to explore lipoprotein metabolism 
due to substantial species specificity. This holds particularly true for conventional 
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laboratory animals such as mice and rats which – unless genetically modified or induced by 
special diet - do not develop atherosclerosis (see review [6]). The same argument is valid for 
investigations using cellular model systems. Since the liver is the central organ responsible 
for lipoprotein metabolism and primary human hepatocytes are of only limited use in 
research, most cellular studies in lipoprotein metabolism have been conducted in human 
hepatoma cells lines. These lines express, secrete and assemble a lipoprotein pattern which 
is substantially different from the respective human counterpart [7]. 
For all these reasons, the in vivo investigation of metabolic pathways in human subjects is 
the ultimate approach to elucidate physiological or pathological functions of metabolites in 
the human body. Historically, such human kinetic studies were performed using radioactive 
tracers; this methodology is, however, nowadays of only restricted use. Therefore, stable-
isotope tracer kinetic studies in human subjects with clear advantages regarding safety and 
technical issues have replaced the radiotracer methods to become an important research tool 
for achieving a quantitative understanding of the dynamics of metabolic processes in vivo.  
The aim of this review is to shortly describe the methodology and illustrate how the 
approach has expanded our understanding of physiological mechanisms as well as the 
pathogenesis of disorders of human lipoprotein metabolism. We will then specifically 
address the assembly mechanism of the atherogenic Lp(a) complex and focus on the kinetics 
of apoB-containing lipoproteins in patients with chronic kidney disease. This patient group 
is well-known for its high risk for atherosclerotic complications and a 10- to 20-fold 
increased cardiovascular mortality compared to the general population [8]. 
2. Principles of tracer technology 
Exogenous and endogenous labelling techniques have been used to study the in vivo 
metabolism of an endogenous molecule, the tracee (see review [4]). In the exogenous 
method, the same molecule, in form of a usually radioactively labelled tracer, is introduced 
into the bloodstream [9]. In lipoprotein studies, this methodology first requires purification 
of the target molecule or particle and ex-vivo radiolabelling followed by reinfusion into the 
circulation. The physological integrity of the target molecule might, however, suffer from 
such procedure. Furthermore, in case of multiprotein complexes (which most lipoproteins 
are), the kinetics of individual protein components cannot be investigated by this approach. 
As an example, the investigation of in vivo kinetics of both protein components of Lp(a), as 
described in this article, to study its assembly mechanism would not be possible with the 
exogenous labelling approach. 
In contrast, in endogenous labelling, a labelled precursor of the molecule of interest, in case 
of proteins usually a labelled amino acid, is used to label the target molecule by infusion 
into the circulation of a suitable proband. Ideally, the tracer can easily be detected and 
quantified, has the same kinetic behaviour as the tracee, and does not perturb the system. 
Usually, kinetic studies are performed in steady state, where the rates of input and output 
for a given unlabelled tracee substance are equal and time invariant. Thus, the information 
provided by the tracer reflects the behaviour of the tracee [10, 11]. At various times, the 
target protein or particle has to be purified from the blood of human probands and the 
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amount of tracer is quantified to provide a kinetic curve. A mathematical model is then 
constructed to extract all the information contained in the kinetic curve. By fitting a model to 
the data, it is possible to calculate the parameters of the model that characterize the flux of 
molecules between kinetically homogeneous pools. For example, it is thus possible to 
investigate the whole pathway including production, conversion or catabolism of 
lipoprotein particles, information that cannot be obtained by static measurements alone. 
The term stable isotope refers to a non-radioactive isotope of a given atom that is less 
abundant in a molecule within a biological system than the lightest naturally occurring 
isotope. The most common stable isotope used as metabolic tracer for apolipoprotein kinetic 
studies is [2H3]-leucine. Stable isotope tracers are much safer than radioactive tracers for 
both the study subject and the investigator. Furthermore, the duration of stable isotope 
experiments is normally less than 24 hours which is much shorter compared to radiotracer 
techniques which may need up to 14 days of examination [9]. 
2.1. Tracer administration 
A tracer can be administered intravenously as either a single bolus injection, a primed 
constant infusion (i.e., a constant infusion given immediately after a priming bolus), or as a 
combination of both. The tracer bolus administration offers superior dynamics compared 
with the primed constant infusion, because the enrichment curves (the tracer ⁄ tracee ratios) 
after a bolus injection correspond to the impulse response of the system. It is therefore 
suitable to study components of lipoprotein metabolism with a slow rate of turnover. 
Another advantage of bolus administration is that it facilitates the determination of newly 
synthesized particles, as the intracellular precursor enrichment is greater at the start of the 
study. This argument therefore counts particularly when investigating kinetics of particle 
assembly, as described in 3.1.1. Practically, the bolus infusion is also most convenient for 
both subjects and investigators. 
2.2. Multicompartment models for data analysis 
Multicompartment modelling is a superior method to dissect the complexities of lipoprotein 
metabolism, and has been widely applied to systems in which material is transferred over 
time between compartments connected in a specific structure to permit the movement of 
material amongst the compartments [12]. 
Each compartment is assumed to be a homogenous entity within which the entities being 
modelled are equivalent. For instance, the compartments may represent different types of 
lipoprotein particles that are kinetically homogeneous and distinct from other material in 
the system. Very often, the data can be described by more than one model. To ensure that 
the best model is selected, it is necessary to carefully examine the fitting of the kinetic curve, 
to determine the precision of the parameter estimates, and to perform statistical tests to 
compare results obtained with different models. However, the complexity of a 
multicompartment model is usually a compromise for what is practically possible. A very 
simple model may not adequately describe the kinetic heterogeneity present within the 
system. A model that is too complex, on the other hand, will not be supported by 
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experimental data and, hence, will have little predictive value. Furthermore, even if the 
development of models is based on experimental data, several assumptions are required in 
order to derive the model that is to be used. Thus, mathematical models do not determine 
the kinetics of lipids directly; rather, they derive an indirect approximation. 
The software SAAM (Epsilon Group, Charlottesville, VA, USA) has become the first choice 
for modelling lipoprotein kinetic studies. The SAAM II program was recently developed by 
SAAM Inst., Inc., Seattle, WA, USA, and is frequently used to analyse lipoprotein tracer data 
using compartmental models [13, 14]. The primary kinetic parameter resulting after 
modelling with SAAM II is the fractional synthesis rate (FSR) which, under steady state 
conditions, is identical to the fractional catabolic rate (FCR) and has the dimension of 
pools/day. The reciprocal value of FSR/FCR is called retention time (RT, given in days) and 
indicates the residence time of the investigated tracee (the target apolipoprotein in our 
cases) in the circulation. The product of FSR multiplied by the concentration of tracee is 
called production rate (PR) and is usually expressed as mg/kg body weight/day. 
3. Metabolism of apoB-containing lipoproteins 
Dietary lipids are absorbed in the intestine and packaged into large, triglyceride-rich 
chylomicrons which undergo lipolysis to form chylomicron remnants. In the last step of the 
so-called exogenous lipoprotein pathway, these particles are finally taken up by the liver. 
The liver then secretes triglyceride-rich lipoproteins known as very low-density lipoproteins 
(VLDLs) representing the first step oft the endogenous lipoprotein pathway (Figure 1). 
Lipoprotein kinetic studies have shown that VLDLs are metabolically heterogeneous. 
Following lipolysis by endothelium-bound lipoprotein lipase (LPL) and hepatic lipase (HL), 
these particles are converted via intermediate-density lipoproteins (IDL, also called VLDL 
remnants) to low-density lipoprotein (LDL) or taken up by the liver. LDL is catabolized 
mainly by the liver or peripheral tissues via the LDL receptor. Increased plasma 
concentrations of LDL are a major risk factor for CVD. ApoB-100 is the major apolipoprotein 
of chylomicrons, VLDL, IDL and LDL. 
Lipoprotein(a) [Lp(a)] consists of an LDL-like particle which is covalently bound to the 
glycoprotein apolipoprotein(a) [apo(a)] by disulfide linkage and derives from the liver [15] 
(Figure 2). Among individuals, Lp(a) plasma concentrations vary more than 1000-fold, 
ranging from less than 0.1 mg/dl to more than 300 mg/dl. Depending on the investigated 
population and the used genetic approach, it has been shown that between 30% and 90% of 
this variation in plasma concentrations of Lp(a) is determined by the apo(a) gene locus, 
encoding proteins from <300 to >800 kDa [16-18]. Apo(a) size is negatively correlated with 
Lp(a) concentrations, such that low-molecular-weight (LMW) apo(a) isoforms express on 
average high Lp(a) plasma concentrations, while high-molecular-weight (HMW) isoforms are 
usually associated with lower concentrations (reviewed in reference [15]). Elevated plasma 
concentrations of Lp(a) have been found associated with an increased risk of developing CVD 
in many studies which was confirmed by recent large meta-analyses [19, 20]. In vivo kinetic 
studies using radio-labeled Lp(a) indicated that the large differences in Lp(a) concentrations 
seen among individuals are determined by synthesis and not degradation [9, 21]. 
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Figure 1. Endogenous metabolic pathway of apolipoprotein B (apoB)-containing lipoproteins. 
Triglyceride-rich very-low-density lipoproteins (VLDL) are synthesized and secreted by the liver into 
the blood stream and their triglycerides catabolized by the endothel-bound enzyme lipoprotein lipase 
(LPL) resulting in intermediate-densitly lipoproteins (IDL). LPL and hepatic lipase (HL) further convert 
IDL to low-density lipoproteins (LDL) which are removed from the circulation by the liver and 
extrahepatic tissue cells via LDL-receptor (LDLR)-mediated endocytosis. Lipoprotein(a) [Lp(a)] is 
synthesized and secreted by the human liver into circulation. 
 
Figure 2. Structure of lipoprotein(a) [Lp(a)]. Lp(a) consists of an LDL-like particle and the disulfide-
bridge-linked glycoprotein apolipoprotein(a) [apo(a)] which exerts high sequence homology to 
plasminogen. Apo(a) consists of an inactive protease domain (blue rectangle) and identical as well as 
non-identical repeats of kringle domains (blue circles). The number of identical kringles vary among 
individuals and gives rise to a genetically determined molecular size polymorphism of apo(a). 
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3.1. Biosynthesis of Lp(a) 
Lp(a) has been the target of extensive and successful research particularly with respect to 
the unusually high degree of genetic control of its expression. In contrast, metabolism and 
physiological roles as well as pathogenicities of Lp(a) are still poorly understood, as recently 
reviewed by Dubé et al. [22]. The mechanisms that control Lp(a) secretion and assembly 
were investigated mostly by means of cellular hepatocyte model systems, yielded 
contrasting results and thus remain highly controversially discussed (see review [23]). 
Assembly of apo(a) and apoB to Lp(a) is generally viewed as a two-step procedure [24, 25]. 
In a first step, distinct domains within the apoB molecule initially associate with apo(a) in a 
non-covalent interaction to bring the two molecules into close proximity. In a second step, a 
disulfide bond is formed between apo(a) cysteine 4057 and apoB cysteine 4326 residues [24, 
26]. Whether this disulfide bond is formed through a spontaneous oxidation reaction or 
through a specific enzymatic reaction is unclear [27, 28]. 
The location of this assembly process is the subject of controversial discussion as well. 
Intracellular, extracellular and/or plasma membrane-associated assembly procedures have 
been reported to occur in various cell systems [23]. Lp(a), like many other oligomeric protein 
complexes, may assemble in the endoplasmic reticulum of the hepatocyte and be secreted as 
a whole particle [29, 30]. Alternatively, newly synthesized apo(a) could bind extracellularly 
to preexisting LDL or VLDL circulating in the plasma. Most authors postulate an 
extracellular assembly of Lp(a) based on studies conducted in various cellular model 
systems. White et al. could not detect an intracellular apo(a)-apoB complex by adding anti-
apo(a) antiserum to the culture medium of primary baboon hepatocytes, but found such 
complexes attached to the plasma membrane. The authors therefore concluded that, in that 
cellular system, Lp(a) is primarily assembled after secretion and to some extent also on the 
plasma membrane [31]. This conclusion has to be, however, critically evaluated since baboon 
hepatocytes secrete most of their apoB as VLDL, which does not associate with apo(a) [32]. 
Similar studies in apo(a)-transfected HepG2 cells could not demonstrate an intracellular 
apo(a)-apoB assembly for this human hepatocyte model and thus confirmed the results from 
the baboon studies [24, 33, 34]. Nevertheless, there is also evidence for intracellular assembly 
of Lp(a) in cell culture systems. Bonen et al. were able to detect an intracellular apo(a)-apoB 
complex in HepG2 cells transfected with an apo(a) minigene [35]. HepG2 cells have been 
reported to secrete a triglyceride-rich lipoprotein particle with an LDL density that does not 
exist at all in human plasma [36]. Taken together, the extracellular Lp(a) assembly proposed by 
numerous in vitro studies needs to be reviewed with caution, because these studies used 
cellular models that do not reflect the physiological lipoprotein metabolism. 
3.1.1. In vivo metabolism of Lp(a) and LDL in healthy subjects 
Kinetic in vivo studies in humans have unfortunately also produced controversial results. 
Krempler et al. injected radiolabeled VLDL in Lp(a)-positive healthy probands and found no 
metabolic relationship between apoB in VLDL or LDL and apoB in Lp(a). The authors 
therefore concluded that Lp(a) seems to be synthesized as a separate lipoprotein 
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independently of other apoB-containing lipoproteins [37, 38]. Two in vivo turnover studies 
using stable-isotope labeling techniques came to the same conclusion: Morrisett et al. and Su 
et al. observed similar synthesis rates of Lp(a)-apo(a) and Lp(a)-apoB [39, 40]. While these 
findings are compatible with an intracellular assembly of nascent apo(a) and apoB to Lp(a), 
two other kinetic studies concluded that Lp(a) originates from de novo hepatic LDL as well 
as from plasma LDL [41, 42]. 
We investigated by stable-isotope technology the metabolism of apo(a) and apoB-100, the 
two major Lp(a) protein components, in comparison to apoB of LDL in nine healthy 
probands. The metabolic data accumulating in this study after appropriate modeling 
present a scenario of virtually complete intracellular assembly of Lp(a) [43]. 
Mean FSR, RT and PR values of apo(a) from Lp(a) were similar to those of apoB from Lp(a) 
but significantly different from the kinetic parameters of LDL-apoB. The differences were 
particularly large between the PR values of LDL and Lp(a) since this parameter takes into 
account plasma concentrations that are much higher for LDL than for Lp(a). 
Tracer/tracee data from Lp(a)-apo(a), Lp(a)-apoB, LDL-apoB and VLDL-apoB were analyzed 
based on the multicompartment model shown in Figure 3 in order to investigate whether 
Lp(a) assembles from circulating LDL or from de novo produced “hepatic” LDL. 92% of 
leucine in Lp(a)-apoB originated from the hepatic apoB pool. The remaining 8% derived 
from plasma LDL-apoB. LDL-apoB stemmed from two sources, namely from VLDL-apoB 
(54%) and from de novo synthesis (46%). 
The kinetic parameters obtained from this in vivo turnover study of Lp(a) metabolism in 
healthy men allow three major conclusions: i) Since FSRs of both protein components of 
Lp(a) is very similar and different from those of LDL, an almost exclusive intracellular 
hepatic Lp(a) assembly can be assumed. This analysis, however, does not allow any 
conclusions to be drawn on where (inside the hepatocyte, at its plasma membrane or, 
eventually, in the space of Dissé) this assembly takes place. ii) Apo(a) FSR/FCR is positively 
related to the number of apo(a) kringle 4 repeats (e.g. apo(a) molecular size), suggesting that 
plasma Lp(a) concentrations are controlled not only by synthesis but also to some smaller 
extent by degradation. iii) Longer plasma RT of apo(a) from probands with LMW apo(a) 
isoforms compared to those with HMW apo(a) isoforms help to explain the potential 
atherogenicity of higher concentrations in carriers with LMW apo(a) isoforms. 
The de novo synthesis of LDL is an absolute prerequisite for the postulated (intra)cellular 
hepatic assembly of Lp(a). Such a “direct” LDL production has been questioned by some 
investigators who presume that it may instead be the consequence of a very fast lipolytic 
pathway [45]. However, metabolic studies of apoB metabolism using stable-isotope 
technology fitted by multicompartmental modeling support a significant “direct” LDL 
production by the liver [46, 47]. A substantial amount of nascent LDL production was also 
detected in cultured primary human hepatocytes [48] but not in HepG2 cells [36]. Lp(a) 
secretion was previously demonstrated in such cells, thus additionally supporting the view 
of “direct” LDL synthesis by human hepatocytes [49]. 
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Figure 3. Multicompartmental model for apoB-100 and apo(a) metabolism. A plasma leucine pool 
(compartment 1) was used as a forcing function, and delay compartments that account for assembly and 
subsequent secretion of apoB-100 (compartment 2) and apo(a) (compartment 6), respectively. ApoB in 
VLDL, LDL, Lp(a), and apo(a) in Lp(a) consist all of single compartments. The input of apoB in Lp(a) is 
twofold: one via de novo synthesis from the liver and one from LDL-apoB. d(i,j) denotes the distribution 
of transfer from the delay compartment j to compartment i and k(i,j) represents the rate constant from 
compartment j to compartment i. In this model, tracer/tracee data for VLDL, LDL, Lp(a) apoB, and Lp(a) 
apo(a) as well as leucine masses (nmol/L) in these compartments were fitted simultaneously. The 
fractional catabolic rate (FCR) of apo(a)-Lp(a) and apoB-Lp(a) was equal to k(0,7) and k(0,5), 
respectively (taken from Frischmann et al. [44], with permission). 
3.2. Lipoprotein metabolism in HD patients suffering from chronic kidney 
disease (CKD) 
Dyslipidemia in patients with CKD and hemodialysis (HD) patients is distinct from other 
organ-specific diseases with far-reaching therapeutic consequences (see review [2]). It involves 
all lipoprotein classes, shows considerable variations depending on the stage of CKD [50, 51] 
and is further modified by concurrent diseases such as diabetes [52] and nephrotic syndrome 
[53]. In addition, major qualitative compositional changes in lipoprotein particles, such as 
oxidation, glycation, carbamylation and formation of small dense LDL (sdLDL – see below) 
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which render the particles more atherogenic, have been observed [54]. Reduced activities of 
plasma cholesterol esterification and cholesterol ester transfer between lipoproteins – key 
factors for the so-called „reversed cholesterol transport“ – result in substantially abnormal 
lipid composition of virtually all lipoprotein classes in HD patients [55]. 
Plasma triglycerides start to increase in early stages of CKD and show the highest 
concentrations in nephrotic syndrome and in patients treated with peritoneal dialysis (PD). 
In pre-dialysis CKD patients, the accumulation of triglycerides is the consequence of both an 
increased PR and a decreased FCR of triglyceride-rich lipoproteins [56]. The increased 
production of triglyceride-rich lipoproteins is possibly a consequence of impaired 
carbohydrate tolerance and enhanced hepatic VLDL synthesis [57]. The reduced catabolism 
is likely due to decreased activities of LPL and HL [58, 59], two endothelium-associated 
lipases that cleave triglycerides into free fatty acids for energy production or storage. 
Diminished catabolism results in the accumulation of IDL particles contributing to 
compositional and size heterogeneity of triglyceride-rich lipoproteins in plasma of CKD 
patients. IDL are rich in apoE, a ligand that is important for removal from the circulation by 
binding to the LDL receptor [60]. The arterial wall therefore is exposed to high plasma 
concentrations of IDL which may predispose to atherosclerosis [54]. 
Elevated plasma concentrations of LDL cholesterol and –apoB are common in nephrotic 
syndrome and PD but do not occur in patients with advanced CKD, treated with HD. There 
are, however, qualitative changes in LDL in patients with CKD and dialysis patients. The 
fraction of sdLDL, which is considered to be highly atherogenic, is increased in HD patients. 
sdLDL is a subtype of LDL which penetrates the vessel wall more efficiently than normal 
LDL, becomes oxidized, and triggers atherosclerotic processes. In addition, sdLDL exert a 
high affinity for macrophages promoting their entry into the vascular wall to participate in 
the formation of foam cells and atherosclerotic plaques [61]. 
In kidney disease, elevated plasma Lp(a) concentrations are not only genetically determined 
but also a consequence of kidney failure [62]. In predialysis CKD patients, Lp(a) concentrations 
are influenced by the glomerular filtration rate (GFR). In patients with HMW apo(a) isoforms 
but not in those with LMW apo(a) isoforms, plasma Lp(a) concentrations begin to increase in 
stage 1 CKD before GFR starts to decrease [50]. This isoform-specific increase in plasma Lp(a) 
concentrations was observed in several but not all studies in CKD and HD patients [50, 62-66]. 
In contrast, in patients with nephrotic syndrome [67, 68] and in PD patients [63], increases in 
plasma Lp(a) concentrations occur in all apo(a) isoform groups, probably as a consequence of 
the pronounced protein loss and a subsequently increased production in the liver [69]. After 
successful kidney transplantation, a decrease in plasma Lp(a) can be observed in HD patients 
with HMW apo(a) isoforms [70, 71] and in PD patients with all apo(a) isoform groups [72]. 
Thus, the elevation of Lp(a) in CKD is due to non-genetic causes, mostly influenced by the 
degree of proteinuria [50, 67] and less by the cause of kidney disease [63]. 
In summary, the hallmarks of uremic dyslipidemia include hypertriglyceridemia and 
increased circulating concentrations of IDL, sdLDL and Lp(a). HD patients are characterised 
by normal LDL concentrations, whereas patients with nephrotic syndrome and CKD 
patients treated by PD are diagnosed with elevated LDL concentrations. 
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3.2.1. Dyslipidemia and CVD in CKD 
Forty years ago, Lindner and colleagues described in their seminal report the excessive risk 
of CVD in HD patients for the first time [73]. Later, Foley et al. extended these observations 
by reporting a 10 to 20 times higher mortality rate in HD patients compared to the general 
population [8]. While in the general population high plasma concentrations of apoB-
containing lipoproteins, low concentrations of HDL cholesterol and high total triglyceride 
concentrations are associated with an increased atherosclerotic cardiovascular risk [74], most 
investigations, including cross-sectional [75-78] and longitudinal [66, 79-87] studies, do not 
support the association between dyslipidemia and CVD in hemodialysed CKD populations 
or even observe opposite associations. Indeed, a worse survival among HD patients has 
been observed with low rather than high BMI [88], blood pressure [89] and serum/plasma 
concentrations of cholesterol [90]. This seemingly paradoxical phenomenon is often called 
„reverse epidemiology“ [91] and exemplified in crossing curves when relating BMI with 
mortality in HD patients and the general population [92]. 
While the BMI-associated death risk shows an almost linear negative gradient in HD 
patients [92], the relationship between plasma total cholesterol and mortality has been found 
to be U-shaped [93]. The group with total cholesterol between 200 and 250 mg/dl had the 
lowest risk for death, whereas those with levels >350 mg/dl had a relative risk of 1.3-fold 
and those with levels <100 mg/dl had a relative risk of 4.2-fold. The association between low 
total cholesterol and increased mortality, however, was reduced after statistical adjustment 
for plasma albumin levels. This dichotomous relationship was confirmed in the Choices for 
Healthy Outcomes in Caring for ESRD (CHOICE) study [94], which showed a nonsignificant 
negative association of cardiovascular mortality with plasma total as well as non–HDL 
cholesterol levels in the presence of inflammation and/or malnutrition; in contrast, there was 
a positive association between total and non–HDL cholesterol and mortality in the absence 
of inflammation or malnutrition. These observations are compatible with the hypothesis that 
the inverse association of total cholesterol levels with mortality in dialysis patients is 
mediated by the cholesterol-lowering effect of malnutrition and/or systemic inflammation 
and not due to a protective effect of high cholesterol concentrations. 
The association of Lp(a) with atherosclerotic complications and CVD has been investigated 
in numerous studies in dialysis patients. Like other atherogenic lipoproteins, Lp(a) has been 
found to contribute to the high cardiovascular burden [66, 79, 84, 95-97]. When apo(a) 
phenotyping was performed along with plasma Lp(a) concentrations, an association 
between the apo(a) K-IV repeat polymorphism and CV complications was consistently 
observed. 
Two final considerations regarding the impact of classical risk factors for the development 
of CVD in CKD patients are, however, worth mentioning: the cardiovascular risk for an 
individual CKD patient at a given time point is the sum (or combination) of risk exposure 
before and after developing CKD. When taking Lp(a) concentrations and apo(a) isoforms as 
an example, a previously healthy subject with low Lp(a) concentrations and a HMW apo(a) 
isoform develops CKD with subsequently rising Lp(a) concentrations covering a relatively 
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short period of his lifespan. A subject with LMW apo(a) isoform, on the other hand, has 
genetically caused elevated Lp(a) concentrations for his whole life which do not substantially 
increase after developing CKD. Since the HMW apo(a) carrier is exposed to elevated 
atherogenic Lp(a) for a much shorter period of his life, this condition has to be considered less 
CVD-prone than having LMW apo(a). This example demonstrates the importance of the 
„longitudinal“ factor when considering risk factors for CVD in CKD patients. 
Finally, as already discussed in the introduction, the quantification of a target parameter 
deemed to be associated with or predictive for a disease can only provide a static picture 
and hardly reflects the true in vivo metabolism. Seemingly normal blood concentrations of 
suspected marker candidates can only be validated by kinetic studies in humans and have 
been therefore performed also in CKD patients. They have provided novel and unexpected 
information regarding the physiology and pathology of atherogenic apoB-containing 
lipoproteins (see review [98]). 
3.2.2. Delayed in vivo catabolism of LDL and IDL in HD patients as potential cause of 
premature atherosclerosis 
For better understanding the atherogeneity of apoB-containing lipoproteins in HD patients 
and to resolve the apparent discrepancy between their obviously impaired lipoprotein 
metabolism and e.g. normal LDL plasma concentrations, we studied the in vivo kinetics of 
VLDL, IDL and LDL by stable isotope technology in HD patients and compared them to 
those of healthy controls [12].  
This study demonstrated for the first time severely decreased FCRs of IDL- and LDL-apoB 
in HD patients as compared to controls (Figure 4), whereas the in vivo kinetics of VLDL did 
not change significantly. A decreased FCR of IDL- and LDL-apoB is identical to a prolonged 
RT of these highly atherogenic particles. The longer RT of these lipoproteins results in an 
extended exposure to oxidation for IDL and LDL in a highly oxidative environment. This is 
in line with experimental data showing a highly significant correlation of 5-hydroxy-2-
aminovaleric acid (HAVA) in LDL, an oxidation product of apoB, with LDL RT in 
normolipidemic controls [99]. In accordance with these results, two previously conducted 
randomized placebo-controlled studies revealed a significant reduction in composite 
cardiovascular disease endpoints when HD patients were treated for two years with 
supplementation of antioxidants such as vitamin E [100] or acetylcysteine [101]. 
Most remarkably, the observed impaired metabolism of apoB-containing lipoproteins is 
accompanied by normal concentrations of LDL-apoB and elevated levels of IDL-apoB 
(Figure 4), in line with previous reports which found increased concentrations of IDL as an 
independent risk factor for atherosclerosis in HD patients [102]. A closer look at the kinetic 
data reveals that the normal concentrations of LDL are the result of a combination of 
decreased FCR and PR. This pattern therefore demonstrates convincingly the strength of 
kinetic studies in contrast to simply quantifying blood concentrations of a target marker 
such as LDL concentrations. Its normal concentrations are masked by two metabolic 
disorders which neutralise each other and result in normal values such as observed in the 
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general population. The altered lipoprotein metabolism therefore puts HD patients at high 
risk for developing atherosclerotic disease despite their normal total and LDL cholesterol 
concentrations. Since most lipid-lowering drugs act by “normalising” the RT of the major 
atherogenic lipoproteins IDL and LDL [103], these drugs are expected to correct some of the 
basic defects of the severely disturbed lipoprotein metabolism in HD patients. Therefore, 
kinetic studies on the impact of lipid-lowering medication on the lipoprotein metabolism in 
CKD patients were a logic consequence of the observed, above-described findings (see 
chapter 3.2.5.). 
 
Figure 4. Kinetic parameters of apoB in LDL, IDL and Lp(a) and apo(a) in Lp(a). Plasma concentrations, 
production rates (PR), fractional catabolic rates (FCR) and residence times (RT) are given for healthy 
controls (green columns) and HD patients (red columns). Columns represent mean values ± SD. Results 
for LDL and IDL are taken from Ikewaki et al. [12], those for Lp(a) from Frischmann et al. [44]. 
Due to the laborious nature of these studies and the complexity of the metabolic modeling, 
only few studies have been performed so far in CKD patients either by radiotracer or stable 
isotope technology. Our kinetic data seem to contrast with a previously published turnover 
study in Finnish HD patients performed with conventional radiotracer techniques. While 
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the authors found decreased LDL clearance rates in predialysis CKD patients [104] they 
could not find a significant difference in LDL-apoB FCR between HD patients and controls 
[105]. More recently, Prinsen et al., by using stable isotopes, found unchanged FCRs for 
LDL-apoB in CKD patients treated with peritoneal dialysis [106]. Chan et al. injected radio-
labeled VLDL into HD patients with or without hyperlipidemia and found decreased FCRs 
of VLDL-apoB and IDL-apoB (the latter only in hyperlipidemic patients) [107]. LDL kinetics 
were not investigated in this study. The reason for these discrepancies is not clear. There 
might be ethnic differences in the lipoprotein metabolism between the investigated patient 
populations of different ethnic origin. One major difference between our and the Finnish 
study is an age difference between patients and controls in our but not in the Finnish study. 
Our control subjects were considerably younger than the HD patients (35 vs. 51 years). At 
first glance, this age difference might explain to some extent the dramatic differences found 
in our study, since LDL clearance rates have been repeatedly described to decrease with age 
presumably due to down-regulated hepatic LDL receptor expression in the elderly [108, 
109]. Based on the results of these studies, an age difference of 15 years (as observed in our 
work) would result in an approximately 10% change in FCR values and could therefore not 
explain the more than two-fold difference in our study. The observed differences in kinetic 
parameters can therefore not be explained by age differences between study groups. 
Several mechanisms may contribute to our observations. First, the diminished LDL 
catabolism in HD patients might be explained by a possible contribution of LDL uptake by 
the healthy human kidney which does not function appropriately (or at all) in chronic 
kidney failure. In fact, glomerular cells like mesangial or epithelial cells have been shown in 
vitro to express lipoprotein receptors and to take up LDL comparably to fibroblasts and 
hepatocytes [110]. It is, however, completely unclear whether the kidney plays a significant 
role in LDL catabolism in vivo. Perfusion studies in rat kidneys indicate that virtually no 
intact LDL is cleared from the circulation by the kidney [111]. Second, an impaired lipolytic 
cascade in HD patients most likely also contributes to our results. The relatively normal 
VLDL concentrations and kinetic parameters and the correspondingly impaired IDL 
parameters are in good accordance with previous findings of normal lipoprotein lipase 
(LPL) but significantly decreased activities of hepatic triglyceride lipase (HL) in HD patients 
[59]. Since HL promotes the conversion of IDL to LDL, a decrease in HL activity might 
contribute to the accumulation of IDL and reduced production rates of LDL (without 
accumulating small, dense LDL) in HD patients. 
3.2.3. Kinetics of Lp(a) in hemodialysis patients 
We previously performed in vivo kinetic studies using stable-isotope techniques to elucidate 
the mechanism for increased plasma Lp(a) concentrations in HD patients [44]. PRs of apo(a) 
and apoB, the two apolipoproteins contained in Lp(a), were normal, when compared to 
control subjects with similar plasma Lp(a) concentrations (Figure 4). The FCR of these 
apolipoproteins was, however, significantly reduced compared to controls resulting in a 
much longer plasma RT for apo(a) of almost 9 days, compared to only 4.4 days in controls. 
Since the PR of Lp(a) did not differ between HD patients and controls, its decreased 
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clearance in HD patients leads to increased Lp(a) plasma concentrations and is likely the 
result of loss in kidney function [44]. A role of the kidney in the catabolism has been 
previously supported by the observation of renovascular arteriovenous differences in Lp(a) 
concentrations [112] as well as apo(a) fragments in urine [113, 114]. 
Comparing kinetic data in HD patients [44] with those in patients with nephrotic syndrome 
[69] points to fundamental differences in the metabolism of Lp(a) and other proteins 
between these two patient groups. Patients with nephrotic syndrome do not differ with 
respect to the FCR of Lp(a) compared to controls but have increased Lp(a) PRs [69]. It is well 
known that nephrotic patients show a generally increased lipoprotein synthesis of 
lipoproteins [115]. Since kidney function is relatively well preserved in nephrotic syndrome, 
a decreased clearance of Lp(a) in these patients is not likely to be expected. Metabolic 
differences between nephrotic and dialysis patients are not only evident for Lp(a) but also 
for albumin. Whereas the FCR of albumin in HD patients is similar or even reduced 
compared to controls, the FCR in patients with nephrotic syndrome is increased [116, 117]. 
3.2.4. Consequences of the impaired metabolism of atherogenic lipoproteins in HD patients 
The observation of markedly decreased FCRs of apoB of LDL and IDL as well as apo(a) and 
apoB in Lp(a) causes a prolonged RT of these highly atherogenic lipoproteins. Due to the 
long retention period, “aged” lipoprotein complexes are thus more susceptible for 
alterations such as oxidation damage, which was shown to be associated with accelerated 
atherogenesis in HD patients [118]. Previous kinetic studies investigated the metabolism of 
the two LDL subclasses, “buoyant” LDL1 and the smaller cholesterol-poor “dense” LDL2, in 
subjects with familial defective apoB-100 (FDB). The authors found a more than four-fold 
longer RT for small dense LDL2 in those patients as compared to normolipidemic controls 
[99]. It was therefore suggested that oxidative damage of an “aged” LDL2, which is present 
in large concentrations in both blood and the subendothelial space, may be an important 
mechanism for the development of premature atherosclerosis in patients with familial 
defective apoB-100. Since the LDL-like particle of Lp(a) is compositionally similar to LDL2 
[41], it is tempting to speculate that the increased RT of circulating Lp(a) might pose an 
additional risk factor for the increased incidence of cardiovascular disease in HD patients. 
3.2.5. Influence of statin treatment on kinetic parameters in hemodialysed patients 
In the general population, therapy with HMG-CoA-reductase inhibitors (statins) which 
inhibit endogenous cholesterol biosynthesis has shown to improve outcome in several 
atherosclerotic diseases [119, 120]. The inhibition of cholesterol biosynthesis subsequently 
leads to up-regulation of LDL receptors and therefore increased clearance and thus 
reduced RT of circulating LDL [103]. Statins also have a beneficial role as anti-
inflammatory agents, which is independent of their lipid-lowering effect. Inflammation is 
highly prevalent in patients with CKD and is consistently associated with cardiovascular 
morbidity and mortality. In line with this metabolic background, the first studies in HD 
patients demonstrated a substantial normalisation of the dyslipidemic plasma profile and 
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reduced progression of renal disease [121, 122] and in one study also reduced mortality 
[123] in these patients. 
In contrast and quite surprisingly, three previously conducted large, randomized, placebo-
controlled trials on statin treatment in CKD patients had not led to significant benefits 
regarding their primary cardiovascular outcome. Two of those studies, the German Diabetes 
Dialysis (4D) Study and the Study to Evaluate the Use of Rusovastatin in Subjects on 
Regular Hemodialysis (AURORA) were performed on HD patients, one study, the 
Assessment of Lescol in Renal Transplantation (ALERT) Study on patients who had 
undergone kidney transplantation. Their primary endpoints (death of cardiovascular cause, 
nonfatal myocardial infarction or nonfatal stroke) were virtually unchanged [124-126]. 
However, there has been a promising risk reduction in the secondary endpoint ‘all cardiac 
events combined’ in one study [126]. A simulated study of exactly the same trial using a 
large historical database with more than 10.000 patients also demonstrated that statin use 
was associated with some benefit [127]. A comprehensive review of outcome data from the 
4D and AURORA trials found no benefit of statin therapy in either the whole study group of 
HD patients or after stratification for inflammatory marker levels [128]. More recently, 
another, much larger trial including 9270 patients with chronic kidney disease, the Study of 
Heart and Renal Protection (SHARP) could show a significant risk reduction in 
cardiovascular events in a mixed population of patients with kidney disease including 2/3 
predialysis and 1/3 HD patients treated with a combination of a statin and ezitimibe. This 
effect did not differ between HD and predialysis patients [129]. 
Based on our previous studies on lipoprotein kinetics in HD patients and the above-
described conflicting results regarding their cardiovascular risk profile after statin 
treatment, we examined by stable-isotope technology the in vivo kinetics of apoB-containing 
particles in HD patients before and after treatment with atorvastatin (Schwaiger et al., 
unpublished). 
In this study we described for the first time effects of HMG-CoA reductase inhibition on 
apoB metabolism in CKD patients treated with HD. Low-dose atorvastatin, given for three 
months to six male patients, lowered, as expected, concentrations of VLDL- and LDL-apoB, 
both accompanied by a significant increase of their FCR, while hepatic production of both 
apolipoproteins was not altered. This led, as expected, to a lower RT of these atherogenic 
apoB-containing particles comparable to RT values of healthy subjects with normal kidney 
function. The observed findings therefore argue for a beneficial effect of statin therapy 
regarding cardiovascular events in HD patients similar to described for the general 
population. 
To understand why statins have surprisingly failed to reduce cardiovascular events in HD 
patients, the basic mechanisms underlying the pathophysiology of CVD in CKD must be 
critically considered. In contrast to the general population, CKD patients suffer, in addition 
to dyslipidemia, from several further complex comorbid conditions including diabetes 
mellitus, hypertension, oxidative stress, inflammation, insulin resistance, anemia and 
disturbances in mineral metabolism. Lipid lowering therapy by statins have the potential to 
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ameliorate only some but no all of those conditions (see review [130]). Taken together, statin 
therapy in CKD maybe recommended based on our kinetic studies on apoB-containing 
lipoproteins, optimally combined with medication to treat atherogenic non-lipid factors in 
HD patients. 
4. Conclusion 
Kinetic in vivo studies in human subjects are superior to many methodological approaches 
including animal and cell culture models and thus represent the ultimate approach to 
understand basic metabolic pathways in humans. They have clearly revolutionized human 
lipoprotein research and have particularly resulted in novel insights into the metabolism of 
atherogenic apoB-containing lipoproteins some of which have been the subject of our 
previous investigations and object of this review. 
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